ECSP088398A - Compuestos tricíclicos útiles como agonistas de receptores de oxitocina - Google Patents

Compuestos tricíclicos útiles como agonistas de receptores de oxitocina

Info

Publication number
ECSP088398A
ECSP088398A EC2008008398A ECSP088398A ECSP088398A EC SP088398 A ECSP088398 A EC SP088398A EC 2008008398 A EC2008008398 A EC 2008008398A EC SP088398 A ECSP088398 A EC SP088398A EC SP088398 A ECSP088398 A EC SP088398A
Authority
EC
Ecuador
Prior art keywords
oxychocine
tricyclic compounds
receptors agonists
useful tricyclic
useful
Prior art date
Application number
EC2008008398A
Other languages
English (en)
Inventor
Lynn Resnick
Zia Rahman
Sharon Joy Rosenzweig-Lipson
Robert H Ring
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088398A publication Critical patent/ECSP088398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen aquí métodos para tratar y prevenir la ansiedad, trastornos relacionados con la ansiedad, esquizofrenia y trastornos relacionados con la esquizofrenia, donde dichos métodos comprenden la administración de agonistas del receptor de oxitocina: de fórmula 1, o una sal farmacéuticamente aceptable de los mismos, donde: G1 es (I); de fórmula 2 o una sal farmacéuticamente de los mismos, donde: G2 es (II).
EC2008008398A 2005-10-24 2008-04-24 Compuestos tricíclicos útiles como agonistas de receptores de oxitocina ECSP088398A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72965605P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ECSP088398A true ECSP088398A (es) 2008-06-30

Family

ID=37834124

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008398A ECSP088398A (es) 2005-10-24 2008-04-24 Compuestos tricíclicos útiles como agonistas de receptores de oxitocina

Country Status (15)

Country Link
US (1) US20070117794A1 (es)
EP (1) EP1948662A2 (es)
JP (1) JP2009512730A (es)
KR (1) KR20080063848A (es)
CN (1) CN101296929A (es)
AU (1) AU2006306547A1 (es)
BR (1) BRPI0617770A2 (es)
CA (1) CA2626180A1 (es)
CR (1) CR9923A (es)
EC (1) ECSP088398A (es)
GT (1) GT200800052A (es)
IL (1) IL190900A0 (es)
NO (1) NO20081835L (es)
RU (1) RU2008114374A (es)
WO (1) WO2007050353A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2954167A1 (fr) 2009-09-04 2011-06-24 Centre Nat Rech Scient Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
CN102905720A (zh) 2010-05-18 2013-01-30 日内瓦大学 催产素样分子的新用途及相关的方法
WO2011146806A1 (en) * 2010-05-21 2011-11-24 University Of Florida Research Foundation, Inc. Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
US9585935B2 (en) * 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
HUE060496T2 (hu) 2015-07-06 2023-03-28 Kinoxis Therapeutics Pty Ltd Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
FI3551631T3 (fi) 2016-12-12 2025-01-16 Kinoxis Therapeutics Pty Ltd Ei-peptidit-oksytosiinireseptoriagonistit
WO2019180269A1 (en) 2018-03-23 2019-09-26 Cytoo Alk5 inhibitors as skeletal muscle hypertrophy inducers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists

Also Published As

Publication number Publication date
KR20080063848A (ko) 2008-07-07
WO2007050353A3 (en) 2007-06-21
CA2626180A1 (en) 2007-05-03
IL190900A0 (en) 2008-11-03
BRPI0617770A2 (pt) 2011-08-09
CN101296929A (zh) 2008-10-29
EP1948662A2 (en) 2008-07-30
RU2008114374A (ru) 2009-12-10
US20070117794A1 (en) 2007-05-24
NO20081835L (no) 2008-05-20
JP2009512730A (ja) 2009-03-26
GT200800052A (es) 2008-10-06
AU2006306547A1 (en) 2007-05-03
WO2007050353A2 (en) 2007-05-03
CR9923A (es) 2008-06-27

Similar Documents

Publication Publication Date Title
ECSP088398A (es) Compuestos tricíclicos útiles como agonistas de receptores de oxitocina
ECSP066520A (es) Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY31430A1 (es) Derivados de piridina y pirazina -83
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
PA8591701A1 (es) Derivados de pirrolopirimidina
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY29184A1 (es) Derivados de sulfonilbencimidazol
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
DE602005023197D1 (de) -muscarinrezeptors
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
CU20100252A7 (es) Derivados de dibenzotiazepina
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
MX2007005199A (es) Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
UY29632A1 (es) Derivados de pirazolopiridina como inhibidores del receptor b(beta)-adrenérgico cinasa 1